Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.47 |
| ▸ | HTR1F | P30939 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953009 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL3228604 | 0.83 | MEN1 (0.46) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL29955768 | 0.78 | CYP2A6 (0.45) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL29956775 | 0.78 | CYP2A6 (0.45) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL29951048 | 0.78 | CYP2A6 (0.42) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL31291618 | 0.77 | MTNR1A (0.57) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL16593217 | 0.76 | HTR1D (0.51) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL3219741 | 0.76 | HTR1D (0.51) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL29954880 | 0.76 | PIM1 (0.41) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B | |
| SCHEMBL19709247 | 0.75 | MTNR1A (0.63) | ALDH1A1CYP1A2CYP2C19MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648867-B1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1648867-B1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ALDH1A1 1171/4885CYP1A2 1147/4885CYP2C19 1356/4885 |
| US-20050288354-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ALDH1A1 1171/4885CYP1A2 1147/4885CYP2C19 1356/4885 |
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | ALDH1A1 196/4885CYP1A2 32/4885CYP2C19 384/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | ALDH1A1 252/4885CYP1A2 183/4885CYP2C19 621/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ALDH1A1 1171/4885CYP1A2 1147/4885CYP2C19 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.